The FDA has approved orforglipron, the first oral GLP-1 receptor agonist for weight management — eliminating the need for weekly injections that have been a barrier for millions of potential patients.
Why This Matters
Current GLP-1 drugs (Ozempic, Wegovy, Mounjaro) require weekly self-injection, which deters many patients. Orforglipron is a once-daily pill taken in the morning, making it as easy as taking a vitamin.
Effectiveness
- Average weight loss: 14.7% of body weight over 36 weeks
- Comparable to injectable semaglutide (Wegovy achieves ~15%)
- Significant improvements in blood sugar, blood pressure, and cholesterol
- Once-daily dosing with no food timing restrictions
Pricing
Eli Lilly is pricing orforglipron at $400/month — significantly less than injectable competitors. Manufacturing pills is cheaper than biologics, which should improve supply issues that plagued the injectable market.
Analysts predict the oral form could double the total GLP-1 market by 2028 as needle-averse patients gain access to this drug class for the first time.
